Search for a trial

A Phase 1 Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4 Antibody) in Subjects with Advanced Solid Tumors

OBJECTIVESPrimary Objectives:To assess the safety and tolerability, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (in the absence of exceeding the MTD) for the…

Companion biomarker development for MEDI4736 treated non-small-cell lung cancer patients using 89Zirconium-labeled MEDI4736 * a feasibility study

To assess the safety and biodistribution of 89Zr-MEDI4736 and its uptake in tumor and target irAE tissues.